- Conditions
- Diabetes Mellitus, Type 2, Hypertension
- Interventions
- EXTEND Plus, EXTEND
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Condition Directory
Diabetes clinical trials
Directory of U.S. ClinicalTrials.gov public records for Diabetes. Browse Diabetes recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 25, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
8332
Shown on this page
12
Current sort
Recently updated
Condition scope
Diabetes
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Diabetes studies are organized in the registry
Generic “diabetes” listings mix type 1, type 2, and gestational diabetes, so the subtype is the first thing to pin down — this directory also has a dedicated type 2 diabetes page. Device studies (continuous glucose monitors, insulin delivery systems) are a large slice of the portfolio and are easiest to find by querying the device term itself.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 265–276 of 8,332 matching trials for Diabetes.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Diabetes (DM)
- Interventions
- Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution
- Drug
- Lead sponsor
- David D'Alessio, M.D.
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Stage 3 Type 1 Diabetes
- Interventions
- AutoCD6-CAR Treg cells
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Sedentary Time, Cardiovascular Diseases, Prediabetes, Obesity
- Interventions
- Blue light, Eating, Standing
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 26 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CagriSema
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Fountain Valley, California • Glendora, California + 37 more
- Conditions
- Resistant Hypertension
- Interventions
- Splanchnic Nerve Denervation, Renal Denervation Only
- Device
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
- Interventions
- Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo, FreeStyle Libre Pro, Deuterated water (2H2O/D2O)
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity & Overweight, Prediabetes
- Interventions
- Precision Nutrition Intervention, Standard Nutrition Counseling
- Behavioral
- Lead sponsor
- Prairie View A&M University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Prairie View, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Standard of care
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 180
- States / cities
- Buena Park, California • Burbank, California • Costa Mesa, California + 144 more
- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 21
- States / cities
- Huntington Park, California • Northridge, California • Santa Ana, California + 18 more
- Conditions
- Diabetes Mellitus, Overweight, Obesity
- Interventions
- NNC0487-0111, Placebo (matched to NNC0487-0111)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Escondido, California • Lomita, California + 12 more
- Conditions
- Diabetes
- Interventions
- MOSES
- Behavioral
- Lead sponsor
- Baltimore Research & Education Foundation, Inc.
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
About this Diabetes clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Diabetes as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Diabetes.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Diabetes.